Search Results
Dedicated Leadership in Life Sciences M&A
Oppenheimer’s Healthcare Investment Banking Group Closes Four Life Sciences M&A Transactions in 2023 Year-to-Date.
Co-Lead Manager on Savara Inc.'s Underwritten Offering
Oppenheimer & Co. Inc. acted as Co-Lead Manager on Savara Inc.’s $79,994,334 Underwritten Offering of Common Stock and Pre-Funded Warrants
Bookrunner on Viking Therapeutics, Inc.'s Follow-On Offering
Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $30.00 per share.
Biopharma Private Placement Insights (Q3'23)
The latest editions of Oppenheimer’s Quarterly Private Placement Insights Report and FDA & IRA Insights Report are now available upon request.
Biopharma Private Placement Insights (Q2'23 and FY'22)
The latest edition of Oppenheimer & Co. Inc.’s Quarterly Biopharma M&A and Strategic Collaboration Insights Report is now available upon request.
Biopharma Private Placement Insights (Q1'23 and FY'22)
The latest edition of Oppenheimer & Co. Inc.’s Quarterly Biopharma M&A and Strategic Collaboration Insights Report is now available upon request.
02/23/2024 Market Commentary
Municipal bond yields held steady this week, bringing muni-Treasury ratios close to three-year lows.
02/16/2024 Market Commentary
The CPI Report released this week showed that inflation continued to ease in January, but not by as much as expected.
02/09/2024 Market Commentary
Heavily influenced by last week's Jobs Report, municipal bond yields and Treasury yields increased this week.
02/02/2024 Market Commentary
The Fed decided to hold rates in place at this week's FOMC meeting, and lowered expectations of a rate cut in March.